Where does Crinetics Pharmaceuticals's cash flow data come from?

Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$127.85M-4.1%	-$122.82M+5.6%	-$130.09M-12.5%	-$115.64M-19.5%	-$96.77M-20.1%
Depreciation and amortization	$1.16M+16.7%	$994K-1.8%	$1.01M+5.5%	$959K+3.7%	$925K+17.4%
Stock-based compensation	$29.68M+36.6%	$21.72M-4.3%	$22.7M-13.1%	$26.12M+27.6%	$20.48M+8.7%
Gain (loss) on sale of assets	-$20K-150%	-$8K—	$0+100%	-$23K-21.1%	-$19K—
Change in accounts receivable	$5.09M—	——	——	——	$0—
Change in inventories	$909K—	——	——	——	$0—
Change in accounts payable	-$12.06M—	——	——	$12.52M+1,023%	-$1.36M-133%
Change in other assets	$7.02M—	——	$7.21M+63.5%	$4.41M-36.3%	$6.92M-11.4%
Change in deferred revenue	-$428K+39.5%	-$707K—	——	——	-$361K-2,051%
Non-cash operating lease expense	$703K+7.5%	$654K—	——	——	$813K+7.1%
Change in operating lease liabilities	-$685K-13.6%	-$603K—	——	——	-$903K-10.5%
Net cash from operating activities	-$124.7M-34.2%	-$92.9M+16.1%	-$110.72M-29.0%	-$85.85M+2.9%	-$88.45M-32.3%
Capital expenditures	$820K+79.0%	$458K-46.9%	$863K-73.0%	$3.2M+158%	$1.24M+20.4%
Purchases of investments	$554.43M+160%	$213.65M-1.4%	$216.7M+18.5%	$182.88M-53.3%	$391.2M-46.0%
Proceeds from maturities/sales of investments	$302.89M+11.7%	$271.21M-29.1%	$382.37M+70.7%	$224.03M-26.9%	$306.48M+66.6%
Net cash from investing activities	-$252.36M-542%	$57.11M-65.3%	$164.81M+334%	$37.95M+144%	-$85.96M+84.1%
Proceeds from issuance of common stock	$380.51M—	$0—	$0—	$0—	$0-100%
Net cash from financing activities	$389.88M+1,398%	$26.04M+744%	$3.08M-56.3%	$7.06M+59.0%	$4.44M-99.2%
Effect of exchange rate changes on cash	-$8K—	——	——	——	$0—
Net increase (decrease) in cash	$12.81M+231%	-$9.76M—	——	-$40.84M+76.0%	-$169.98M—
Accretion (Amortization) of Discounts and Premiums, Investments	$2.22M-18.8%	$2.73M-24.1%	$3.6M-23.6%	$4.71M+7.7%	$4.38M+5.1%
Operating lease liabilities	-$685K-13.6%	-$603K—	——	——	-$903K-10.5%
Increase (Decrease) in Prepaid Expense and Other Assets	$7.02M—	——	$7.21M+63.5%	$4.41M-36.3%	$6.92M-11.4%
Operating lease right-of-use asset amortization	$703K+7.5%	$654K—	——	——	$813K+7.1%
Proceeds From Sale And Maturity Of Available For Sale Securities	$302.89M+11.7%	$271.21M-29.1%	$382.37M+70.7%	$224.03M-26.9%	$306.48M+66.6%
Payments Of Stock Issuance Costs	$578K—	$0—	——	——	$0-100%
Proceeds from exercise of stock options and shares issued under Employee Stock Purchase Plan	——	$10.15M0.0%	$10.15M0.0%	$10.15M0.0%	$10.15M-9.0%
Amounts accrued for offering costs	$165K—	——	——	——	$0—
Accrued payables for capital expenditures	$464K+39.8%	$332K—	——	——	$264K+124%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	-$8K—	——	——	——	$0—
Increase Decrease In Operating Lease Liability	-$685K-13.6%	-$603K—	——	——	-$903K-10.5%
Stock options exercised receivable	$3K—	——	$4.37M+1,134%	$354K+2,260%	$15K-77.3%
Private company shares received under licensing arrangements	——	$0—	$0—	$0—	$0—
Stock held in trust	$920K—	——	——	$112K—	$0—
Free cash flow	-$125.52M-34.5%	-$93.36M+16.3%	-$111.58M-25.3%	-$89.05M+0.7%	-$89.69M-32.1%
Free cash flow	-$125.52M-34.5%	-$93.36M+16.3%	-$111.58M-25.3%	-$89.05M+0.7%	-$89.69M-32.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Crinetics Pharmaceuticals's cash flow data come from?: Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.